gsk-2816126 and Inflammatory-Bowel-Diseases

Enhancer of zeste homolog 2 (EZH2)-mediated trimethylation of histone 3 lysine 27 (H3K27Me3) is critical for immune regulation. However, evidence is lacking to address the effect of EZH2 enzyme's activity on intestinal immune responses during inflammatory bowel disease (IBD). Here we report that suppressing EZH2 activity ameliorates experimental intestinal inflammation and delayed the onset of colitis-associated cancer. In addition, we identified an increased number of functional MDSCs in the colons, which are essential for EZH2 inhibitor activity. Moreover, inhibition of EZH2 activity promotes the generation of MDSCs from hematopoietic progenitor cells in vitro, demonstrating a previously unappreciated role for EZH2 in the development of MDSCs. Together, these findings suggest the feasibility of EZH2 inhibitor clinical trials for the control of IBD. In addition, this study identifies MDSC-promoting effects of EZH2 inhibitors that may be undesirable in other therapeutic contexts and should be addressed in a clinical trial setting.

Topics: Animals; Cell Differentiation; Colitis; Colon; Colonic Neoplasms; Dextran Sulfate; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Female; Hematopoietic Stem Cells; Histone Code; Histones; In Vitro Techniques; Indazoles; Indoles; Inflammatory Bowel Diseases; Methylation; Mice; Myeloid-Derived Suppressor Cells; Pyridones